Oncology News | pharmaphorum

News

BMS lawsuit claims AZ's Imjudo infringes Yervoy patents

AstraZeneca followed a long and arduous road to bring its CTLA4 inhibitor Imjudo to market, and will now have to defend its new product from a patent infringement complaint brought by Brist

News

Jazz swings on ASCO-GI data for zanidatamab

Jazz Pharma's $325 million gamble on rights to Zymeworks' HER2-directed bispecific antibody zanidatamab was the largest in its history, and seems like a safer bet after a mid-stage readout

News

ASCO-GI data sets up wider use of Ipsen's Onivyde

Ipsen and partner Servier hope to extend the uses of their pancreatic cancer therapy Onivyde into the first-line treatment setting, assisted by new phase 3 data reported at the ASCO-GI 2023

News

Takeda grabs ex-China fruquintinib rights from Hutchmed

Chinese biotech Hutchmed's push to sign partnerships for its drug products outside its home market has resulted in a $1.13 billion deal with Japan's Takeda, including a hefty upfront fee of

News

BeiGene's Brukinsa FDA approved for CLL/SLL

Beijing-based pharma, BeiGene’s

News

Roche's Tecentriq to be filed for early-stage liver cancer

A regimen of Roche's Tecentriq and Avastin has become the first immunotherapy-based combination to reduce the risk of liver cancer returning after surgery to remove the tumour in a phase 3

BMS lawsuit claims AZ's Imjudo infringes Yervoy patents

Jazz swings on ASCO-GI data for zanidatamab

ASCO-GI data sets up wider use of Ipsen's Onivyde

Takeda grabs ex-China fruquintinib rights from Hutchmed

BeiGene's Brukinsa FDA approved for CLL/SLL

Roche's Tecentriq to be filed for early-stage liver cancer

CMS aims for broader GLP-1 access via federal programmes

How to meet your physicians where they are online

News

Editor's Picks